Title:
HETEROCYCLIC COMPOUND
Document Type and Number:
WIPO Patent Application WO/2024/071371
Kind Code:
A1
Abstract:
The present disclosure provides a heterocyclic compound. The disclosure relates to a compound in which a ligand of a specific E3 ligase is bound to an intracellular target protein ligand via a linker. More specifically, the disclosure relates to a compound that induces the degradation of a target protein using a ligand of an inhibitor of apoptosis protein (IAP) that is an E3 ligase. The compound of the disclosure exhibits an effect of inducing protein degradation by using the ligand of the inhibitor of apoptosis protein (IAP). Therefore, the compound of the disclosure is useful as a therapeutic agent and/or a prophylactic agent.
Inventors:
IWATA YASUHIRO (JP)
TAKAHASHI NOBUYUKI (JP)
TAKAHASHI NOBUYUKI (JP)
Application Number:
PCT/JP2023/035592
Publication Date:
April 04, 2024
Filing Date:
September 29, 2023
Export Citation:
Assignee:
UBIENCE INC (JP)
International Classes:
C07D471/04; A61K31/496; A61K31/506; A61P43/00
Attorney, Agent or Firm:
KAMADA, Mitsunori et al. (JP)
Download PDF:
Previous Patent: CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE
Next Patent: OXIDATIVE CLEAVAGE METHOD OF TROLOX AMIDE
Next Patent: OXIDATIVE CLEAVAGE METHOD OF TROLOX AMIDE